Neuronetics Inc
NASDAQ:STIM
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Neuronetics Inc
NASDAQ:STIM
|
US |
|
C
|
CJ ENM Co Ltd
KOSDAQ:035760
|
KR |
|
T
|
Top Wealth Group Holding Ltd
NASDAQ:TWG
|
HK |
Neuronetics Inc
Neuronetics, Inc. commercial stage medical technology company, which engages in the designing, developing and marketing products for the patients suffering from psychiatric disorders. The company is headquartered in Malvern, Pennsylvania and currently employs 175 full-time employees. The company went IPO on 2018-06-28. The firm is focused on designing, developing, and marketing products for patients who suffer from neurohealth disorders. Its commercial product, the NeuroStar Advanced Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulation (TMS) to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The NeuroStar Advanced Therapy System is used to treat adult patients with major depressive disorder (MDD). The firm intends to continue to pursue development of its NeuroStar Advanced Therapy System for additional indications. The firm sells its NeuroStar Advanced Therapy System and recurring treatment sessions in the United States. Its primary focus is on selling to psychiatrists, with primary care physicians and pain management specialists.
Neuronetics, Inc. commercial stage medical technology company, which engages in the designing, developing and marketing products for the patients suffering from psychiatric disorders. The company is headquartered in Malvern, Pennsylvania and currently employs 175 full-time employees. The company went IPO on 2018-06-28. The firm is focused on designing, developing, and marketing products for patients who suffer from neurohealth disorders. Its commercial product, the NeuroStar Advanced Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulation (TMS) to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The NeuroStar Advanced Therapy System is used to treat adult patients with major depressive disorder (MDD). The firm intends to continue to pursue development of its NeuroStar Advanced Therapy System for additional indications. The firm sells its NeuroStar Advanced Therapy System and recurring treatment sessions in the United States. Its primary focus is on selling to psychiatrists, with primary care physicians and pain management specialists.
Revenue: Total Q4 revenue was $41.8 million, up 86% year-over-year; adjusted pro forma revenue grew 23% versus prior year.
Profitability: Company achieved positive operating cash flow in Q4 ($0.9 million) but reported a net loss of $7.2 million ($0.10 per share); Q4 EBITDA was negative $4.3 million, an improvement versus negative $11.0 million a year ago.
Clinic momentum: Greenbrook clinic revenue was $23.5 million in Q4 (up 37% adjusted pro forma); total treatment volume up 18% YoY in Q4 and clinic referrals and outreach accelerated meaningfully.
NeuroStar: NeuroStar revenue was $18.3 million in Q4 (pro forma +9%); shipped 49 systems in the quarter with strong ASPs and treatment session revenue of $12.4 million (pro forma +6%).
Guidance: 2026 revenue guide $160M–$166M (midpoint >9% growth vs 2025); Q1 revenue guide $33M–$35M; full-year gross margin guide 47%–49%; operating cash flow expected negative $13M to negative $17M for 2026 with positive cash flow in H2.
Strategic pipeline: Company is preparing clinics for a potential COMP360 (psilocybin) launch with Compass Pathways and expects limited incremental clinic investment if approved.
Leadership and balance sheet: CEO transition announced (Dan Reuvers to become CEO March 23); company paid $5.0 million to amend Perceptive debt and ended Q4 with $34.1 million total cash ($28.1M cash & equivalents, $6.0M restricted).
